Pharma BD Deal Intelligence
Bristol-Myers Squibb Company / Agenus Inc.
2017 · Licensing/Option · $1.6B · Complete
Announcement Sentiment
93
Strongly positive
Outcome Score
45
Mixed — partial payoff, real shortfalls.
BMS licensed Agenus' next-generation anti-CTLA-4 antibody AGEN1181 designed to enhance anti-tumor immunity beyond ipilimumab.
Key facts
- Announced Nov 28, 2017
- Deal value $1.6B
- Deal type Licensing/Option
- Therapeutic area Oncology
- Indications Solid tumors
- Key assets AGEN1181
- Mechanism Anti-CTLA-4 monoclonal antibody (Fc-enhanced)
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals